RESUMEN
We aimed to investigate the diagnostic accuracy of Screening Corneal Objective Risk of Ectasia (SCORE) Analyzer software using ANTERION, a swept-source optical coherence tomography device, for keratoconus diagnosis in an Asian population. A total of 151 eyes of 151 patients were included in this retrospective study as follows: 60, 45, and 46 keratoconus, keratoconus suspects, and normal control eyes, respectively. Parameters in the SCORE calculation, including six indices, were compared for the three groups. The receiver operating characteristic curve analysis and cut-off value were estimated to assess the diagnostic ability to differentiate keratoconus and keratoconus suspect eyes from the normal group. The SCORE value and six indices were significantly correlated-"AntK max" (R = 0.864), "AntK oppoK" (R = 0.866), "Ant inf supK" (R = 0.943), "Ant irre 3mm" (R = 0.741), "post elevation at the thinnest point" (R = 0.943), and "minimum corneal thickness" (R = -0.750). The SCORE value showed high explanatory power (98.1%), sensitivity of 81.9%, and specificity of 78.3% (cut-off value: 0.25) in diagnosing normal eyes from the keratoconus suspect and keratoconus eyes. The SCORE Analyzer was found to be valid and consistent, showing good sensitivity and specificity for keratoconus detection in an Asian population.
RESUMEN
AIM: To evaluate the quantitatively changes in lipid layer thickness (LLT) when 3% diquafosol eye drop is used for dry eye patients using the tear film interferometer. METHODS: A total 124 participants (32 males, 92 females; mean age, 28.9y) diagnosed with dry eye disease (DED) received topical instillation of 4 ophthalmic solutions in one eye: diquafosol, normal saline, 0.1% sodium hyaluronate and 0.3% gatifloxacin, in a masked manner. LLT was measured using an interferometer at baseline and 20min after the instillation of each ophthalmic solutions. RESULTS: Changes of LLT after instillation (nm, mean± standard error) were as follows: 12.6±2.0 for diquafosol (P<0.001), 1.2±2.2 for normal saline (P=0.301), 1.5±2.0 for hyaluronate (P=0.495), and 0.5±3.2 for gatifloxacin (P=0.884). CONCLUSION: Topical instillation of diquafosol increases tear film LLT in DED patients. Diquafosol 3% eye drop might be effective treatment option of evaporative DED with meibomian gland dysfunction.
RESUMEN
BACKGROUND/AIMS: To evaluate the 2-year efficacy of photodynamic therapy (PDT) combined with intravitreal injection of anti-vascular endothelial growth factor (anti-VEGF) in patients with polypoidal choroidal vasculopathy (PCV). METHODS: Twenty-two eyes of 22 patients with PCV followed up for ≥24 months after PDT and anti-VEGF combination therapy were retrospectively reviewed. The patients received intravitreal anti-VEGF (1.25 mg bevacizumab or 0.5 mg ranibizumab) within 7 days after PDT. Eyes were retreated with PDT and anti-VEGF injection, or with only anti-VEGF injection, when indicated. Main outcome measures were best-corrected visual acuity (BCVA) and central foveal thickness (CFT). RESULTS: The mean baseline BCVA (0.43±0.33 logarithm of the minimum angle of resolution, logMAR) was 0.28±0.24 at 12 months (p<0.05 vs. baseline) and 0.39±0.28 at 24 months (not significant). At 24 months, BCVA improved by ≥0.3 logMAR in 27.3% of the eyes, did not significantly decrease in 59.1%, and decreased by ≥0.3 logMAR in 13.6%. The mean CFT was 269.4±134.5 µm at baseline and significantly decreased to 139.6±45.8 µm (12 months) and 199.6±72.9 µm (24 months). PDT was administered 1.45±0.86 times and anti-VEGF injected 4.45±1.36 times over the 24-month period. CONCLUSION: Combined PDT and anti-VEGF injection were effective for 2 years in PCV patients. Visual acuity significantly improved during year 1, but the benefit diminished in year 2. Further investigations are required to determine how to prolong the therapeutic effect of combination therapy for PCV.